CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 101 enrolled
Drug / intervention
xopenexdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00585039
NCT00585039Phase 4Completed
CompareCT.gov

Comparison of Hospital Admission Rates and Plasma(s)-Albuterol Levels in Children Treated With Racemic Albuterol Versus Levalbuterol for Acute Asthma Exacerbations: A Randomized Double-Blind Clinical Trial

Phoenix Children's Hospital·interventional·Posted Jan 2, 2008·Updated Feb 10, 2026

In Brief

A Phase 4 clinical trial evaluating xopenex for Asthma. Completed, enrolled 101 participants across 1 site.

Detailed Summary

The purpose of this study is to determine in a large, double-blind, randomized, prospective pediatric clinical trial whether the use of continuous levalbuterol (Xopenex) in addition to standard emergency department treatment for acute asthma exacerbations will improve the Forced Expiratory Volume in 1 sec (FEV 1) compared to the use of continuous racemic albuterol. The secondary objective is to correlate clinical (hospitalization rates and clinical asthma scores) with plasma levels of (S)-albuterol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2, 2008
Enrollment StartSep 1, 2005
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.5 years ago

Interventions

xopenexdrug

will receive xopenex rather than albuterol to treat acute exacerbation